user

Characterization of pegylated (40kDa) interferon alfa-2A (Pegasys™) in the elderly.

被引：0
|
作者：
Martin, NE
Modi, MW
Reddy, KR
机构：
[1] Hoffmann La Roche Inc, Nutley, NJ 07110 USA
[2] Univ Miami, Miami, FL 33152 USA
来源：
HEPATOLOGY | 2000年 / 32卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
755
引用
下载
收藏
页码：348A / 348A
页数：1
相关论文
共 50 条
  • [21] Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD)
    Reddy, KR
    SEMINARS IN LIVER DISEASE, 2004, 24 : 33 - 38
  • [22] Pegylated (40 kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin:: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study
    Fried, MW
    Shiffman, ML
    Reddy, RK
    Smith, C
    Marino, G
    Goncales, F
    Haeussinger, D
    Diago, M
    Carosi, G
    Zarski, JP
    Hoffman, J
    Yu, J
    GASTROENTEROLOGY, 2001, 120 (05) : A55 - A55
  • [23] Pegylated 40kDA IFN alfa-2a plus amantadine (AMA) or ribavirin (RBV) in naives with chronic hepatitis C (CHC): The HIMPCT (Hepatitis Italian Multicenter Pegasys Amantadine Cooperative Trial)
    Ideo, G
    Angelico, M
    Chirianni, A
    Craxi, A
    Di Perri, G
    Minoli, L
    Montalto, G
    Picciotto, A
    Rizzetto, M
    Ruggiero, G
    Scalzini, A
    Sarracino, M
    JOURNAL OF HEPATOLOGY, 2002, 36 : 112 - 112
  • [24] Phase I study of a 40kDa branched pegylated-interferon α-2a (PEGASYS™) in patients with advanced renal cell carcinoma (RCC).
    Motzer, R
    Berg, W
    Rakhit, A
    Ginsberg, M
    Rittweger, K
    Fettner, S
    Yu, R
    Hooftman, L
    ANNALS OF ONCOLOGY, 2000, 11 : 74 - 75
  • [25] Efficacy of pegytlated (40kDa) interferon alfa-2A (Pegasys™) in randomized trials of patients with chronic hepatitis C with and without cirrhosis:: Correlation of virologic responses with baseline liver histology and genotype.
    Pockros, PJ
    Heathcote, EJ
    Shiffman, ML
    Bain, VG
    Zeuzem, S
    Rustgi, VR
    Desmond, PV
    Dhumeaux, D
    Mills, P
    DePamphilis, J
    Hoffman, DH
    HEPATOLOGY, 2000, 32 (04) : 442A - 442A
  • [26] A randomised controlled trial on pegylated interferon alfa-2a (40KD) (pegasys) or ifn alfa-2a (roferon-a) plus ribavirin (RBV) and amantadine (AMA) vs IFN alfa-2a and RBV in naive patients with chronic HCV
    Mangia, A
    Ricci, GL
    Minerva, N
    Persico, M
    Carretta, V
    Bacca, D
    Cela, M
    Piattelli, M
    di Festi, D
    Annese, M
    Guadagnino, V
    Spirito, F
    Andriulli, A
    JOURNAL OF HEPATOLOGY, 2003, 38 : 153 - 153
  • [27] Pegylated interferon alfa-2a (40KDA) as a monotherapy or in combination with ribavirin significantly improves end of treatment response rate in hepatitis C virus genotype 4 chronic active hepatitis patients
    SAUDI MEDICAL JOURNAL, 2003, 24 : S92 - S92
  • [28] Treatment with 40 kDa peginterferon alfa-2a (PEGASYS®) in combination with ribavirin significantly enhances quality of life compared with interferon alfa-2b plus ribavirin.
    Hassanein, TI
    Cooksley, G
    Sulkowski, M
    Smith, C
    Marinos, G
    Lai, MY
    Pastore, G
    Trejo-Estrada, R
    Vale, AHE
    Lok, AS
    Lin, A
    Green, J
    HEPATOLOGY, 2001, 34 (04) : 243A - 243A
  • [29] Histologic improvement following treatment with once weekly pegylated interferon alfa-2a (Pegasys™) and thrice weekly interferon alfa-2a (Roferon™)in patients with chronic hepatitis C and compensated cirrhosis.
    Balart, LA
    Lee, SS
    Schiffman, M
    Reindollar, R
    Minuk, G
    Pockros, P
    Hoffman, J
    Depamphilis, J
    GASTROENTEROLOGY, 2000, 118 (04) : A961 - A961
  • [30] Pegasys - Peginterferon alfa-2a - Roche
    不详
    FORMULARY, 2002, 37 (12) : 611 - 612
12345